Physician profile
Gerald S Kidd
NPI 1265552210
$7,748.27
in general payments reported to CMS, 2019-2025
29 companies · $2,391 in 2025
The $2,391 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $784 · 2022: $1,264 · 2023: $1,557 · 2024: $1,753 · 2025: $2,391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,677 · Education: $22.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,677.27 |
| Education | $22.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,422.52 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $741.76 | 2021-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $616.10 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $560.70 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $503.32 | 2021-2025 | Xifaxan, Trulance |
| Qol Medical, LLC | $338.54 | 2021-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $317.82 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $256.64 | 2022-2025 | Dupixent |
| Genzyme Corporation | $239.47 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $231.63 | 2023-2025 | Zenpep |
| Lilly USA, LLC | $171.63 | 2023-2025 | Omvoh |
| Celgene Corporation | $164.48 | 2021-2023 | Zeposia |
| Celltrion USA INC. | $121.94 | 2023-2025 | Vegzelma, Yuflyma |
| Madrigal Pharmaceuticals | $121.46 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $118.55 | 2023-2025 | Ocaliva |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $117.04 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $111.56 | 2023-2024 | Linzess |
| Pfizer INC. | $105.39 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $105.05 | 2022 | |
| Phathom Pharmaceuticals, INC. | $66.06 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $58.01 | 2023-2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $56.70 | 2024-2025 | Iqirvo |
| Fresenius Kabi USA, LLC | $47.88 | 2023 | Idacio |
| Ferring Pharmaceuticals INC. | $45.99 | 2021-2022 | |
| Alfasigma USA, INC. | $29.57 | 2022 | |
| Organon LLC | $22.80 | 2023 | Renflexis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.26 | 2023 | Cyltezo |
| Mirum Pharmaceuticals, INC. | $18.83 | 2025 | Livmarli |
| Novo Nordisk INC | $16.57 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Kidd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.